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Abstract
We reported previously that Artemisinin (ART), a widely used anti-malarial drug, is an inhibitor of in vitro HCV subgenomic
replicon replication. We here demonstrate that ART exerts its antiviral activity also in hepatoma cells infected with full
length infectious HCV JFH-1. We identified a number of ART analogues that are up to 10-fold more potent and selective as
in vitro inhibitors of HCV replication than ART. The iron donor Hemin only marginally potentiates the anti-HCV activity of
ART in HCV-infected cultures. Carbon-centered radicals have been shown to be critical for the anti-malarial activity of ART.
We demonstrate that carbon-centered radicals-trapping (the so-called TEMPO) compounds only marginally affect the anti-
HCV activity of ART. This provides evidence that carbon-centered radicals are not the main effectors of the anti-HCV activity
of the Artemisinin. ART and analogues may possibly exert their anti-HCV activity by the induction of reactive oxygen species
(ROS). The combined anti-HCV activity of ART or its analogues with L-N-Acetylcysteine (L-NAC) [a molecule that inhibits ROS
generation] was studied. L-NAC significantly reduced the in vitro anti-HCV activity of ART and derivatives. Taken together,
the in vitro anti-HCV activity of ART and analogues can, at least in part, be explained by the induction of ROS; carbon-
centered radicals may not be important in the anti-HCV effect of these molecules.
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Introduction
Worldwide, an estimated 180 million people are chronically
infected with the hepatitis C virus (HCV) [1]. The current therapy
consists of pegylated interferon a (peg-IFNa), Ribavirin (RBV) in
combination with either the protease inhibitor (PI) Telaprevir or
Boceprevir. This combination therapy has been reported to be
effective in up to 79% of the treated patients infected with HCV
[1,2]. PIs and many of the selective inhibitors of HCV replication
that target the viral genome (including most of those in advanced
clinical development) select rapidly for drug-resistant variants [3].
Alternatively, host targeting antivirals, such as the cyclophilin-
binding molecule Alisporivir, have a high barrier to resistance
[4,5].
Artemisinin (ART), a sesquiterpene lactone with an endoper-
oxide function isolated from the plant Artemisia annua L, is widely
used as an anti-malarial drug [6–8]. The drug has also been
reported to exert anti-bacterial, anti-inflammatory and anti-
angiogenic activities [9–12]. However, because of its low solubility
and poor oral bioavailability, its therapeutic efficacy is not optimal
[11,13]. To combat these hurdles, numerous ART analogues were
synthesized and evaluated for their potential anti-microbial effect
[14]. Interestingly, some of these compounds exhibited, in vitro,
anti-herpes viruses, anti-human cytomegalovirus, anti-human
immunodeficiency virus and anti-hepatitis B virus activity [15–
19]. We reported earlier that ART inhibits in vitro HCV replicon
replication at concentrations that have no effect on host cell
growth [24].
Here we report on the discovery of ART analogues that are
more potent and selective inhibitors of HCV replication than the
parent compound and propose by which mechanism they may do
so.
Materials and Methods
Compounds
Artemisinin, Hemin and TEMPO compounds were purchased
from Sigma (Bornem, Belgium). Artemisinin analogues (Fig. 1 and
2) were synthesized by methods that will be reported elsewhere
[20].
HCV Replicon Assay
Cells carrying HCV replicons I389luc-ubi-neo/NS3-39/5.1
(Huh 5-2) were kindly provided by Prof. R. Bartenschlager
(University of Heidelberg, Germany). Cells were cultured in
Dulbecco’s modified Eagle’s Medium (DMEM, Gibco, Merelbeke,
Belgium) supplemented with 10% heat-inactivated fetal bovine
serum (Integro, Zaandam, The Netherlands), 16 non-essential
amino acids, 100 IU/mL penicillin (Gibco), 100 mg/mL strepto-
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mycin (Gibco), and 250 mg/mL G418. Cell cultures were
maintained at 37uC with 5% CO2.
Antiviral Assay in HCV Replicon Cells
The antiviral assay was performed as described [21,22]. Briefly,
cells were seeded at a density of 56103 cells per well in 96-well cell
culture plates in DMEM containing 250 mg/mL G418 at 37uC
(5% CO2). After 24 hours of incubation, medium was replaced
with fresh DMEM (without G418) and serial dilutions of the test
compounds. Replicon RNA levels were determined by a
quantitative reverse transcription polymerase chain reaction
(qRT-PCR) or quantified by measuring the firefly luciferase
activity in 96-well cell culture plates (Safire, Tecan, Austria).
Antiviral Assay in the HCV Infectious System
The highly infectious HCV JFH-1/CS-N6 described by
Delgrange et al [23] was used for the antiviral assays. A total of
7.26103 Huh 7.5.1 cells per well of a 96-well cell culture plate
were incubated with the virus at specific infectivity of about 400
(400 HCV RNA copies per foci-forming unit [24]) and at the same
time with serial dilutions of compounds. Following 3 days of
incubation, medium was removed and cells were washed once and
lysed to extract the intracellular RNA with the RNeasy kit
(Qiagen). HCV RNA was quantified by means of qRT-PCR [25].
Figure 1. Structural formulae of Artemisinin and synthetic derivatives belonging to the first category AJ.
doi:10.1371/journal.pone.0081783.g001
Figure 2. Structural formulae of Artemisinin and synthetic derivatives belonging to the second category TVN.
doi:10.1371/journal.pone.0081783.g002
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qRT-PCR Assay
A qRT-PCR mixture contained: cellular RNA extract, HCV
JFH-1 forward primer SF-JFH86 [59-TGG CGT TAG TAT
GAG TGT CGT ACA GCC TCC A-39], reverse primer SR-
JFH194 [59-AAA GGA CCC AGT CTT CCC GGC AAT T-39],
and probe [59-FAM-TGG TCT GCG GAA CCG GTG AGT
ACA CC-TAMRA-39], was performed at 50uC for 30 min,
subsequent 15 min at 95uC and PCR amplification of 40 cycles of
denaturation at 94uC for 20 s and annealing and extension at
60uC for 1 min in an ABI 7500 Taqman (Live Technologies).
Cytostatic Assay
Cells were seeded at a density of 56103 or 7.26103 cells per well
in a 96-well plate in complete DMEM in serial dilutions of the test
compounds for Huh 5-2 and Huh 7.5.1 cells, respectively. After
three days of incubation, cell viability was determined by MTS/
PMS method (Promega). The 50% cytotoxic concentration (CC50)
was defined as the concentration that inhibited the proliferation of
exponentially growing cells by 50%.
Drug Combination Studies
The effects of drug combinations were evaluated in a checker-
board format using the method of Prichard and Shipman [26].
The theoretical additive effect was calculated from the dose–
response curves of individual compounds by the equation
Z=X+Y(12X), where X represents the inhibition produced by
first compound alone and Y the inhibition by the second
compound alone. Z represents the effect produced by the
combination of the first with the second compound. The
theoretical additive surface is subtracted from the actual experi-
mental surface, resulting in a horizontal surface that equals the
zero plane when the combination is additive. A surface that lies
above the zero plane indicates a synergistic effect of the
combination, and a surface below the zero plane indicates an
antagonism. For each combination, three independent experi-
ments were carried out to measure the dose–response curves of
each individual compound and the combinations thereof.
Results
Novel Analogues of ART with Improved in vitro anti-HCV
Activity
ART inhibits, as we demonstrated earlier, the in vitro replication
of HCV subgenomic replicons (genotype 1b) in a selective and
dose-dependent manner [27]. Here, we studied whether ART is
also effective in hepatoma cells infected with the infectious HCV
JFH-1. ART was found to inhibit HCV replication in a dose-
dependent manner with EC50 value of 167638 mM. At the
highest concentration tested (400 mM), the host cell proliferation
and cell viability were not affected (Fig. 3 and Table S1). Well
known derivatives of ART such as Artesunate (ARS), Artemether
(ARM) and Dihydroartemisinin (DHA) were found to be highly
toxic in our hepatoma cell cultures (CC50,6 mM).
We next assessed the antiviral activity of novel ART derivatives
(all were recently synthesized with the aim to improve the anti-
malarial properties of this class of drugs [20]) belonging to three
different categories (AJ, TVN and DW). The chemical structures
of ART and the compounds of category AJ are depicted in
Figure 1. All compounds of this group were found to be more
active against HCV-cell culture (HCVcc) than ART (Fig. 3, Table
S1). The EC50 values were 2665, 1562, and 1664 mM for AJ-
001, AJ-002 and AJ-004, respectively. The antiviral effect of these
analogues was next assessed in the subgenomic HCV replicon
system (Huh 5-2). The compounds exert anti-HCV activity against
the genotype (1b) subgenomic replicon with AJ-001 and AJ-004
being the most potent with EC50 values of 8.862.7 and
3.262.4 mM, respectively (Table 1). Category TVN consists of 3
analogues (Fig. 2), of which TVN4 inhibits the replication of the
infectious HCV at EC50 = 5966 mM (Fig. 3) while inhibiting the
subgenomic replicon at EC50 = 36616 mM (Table 1). TVN2 and
TVN6 had weak activities against the infectious HCV JFH
(.70 mM). Of the 30 compounds of category DW (Figure S1),
only one, i.e. DW 13, exerts anti-HCV activity at non-toxic
concentrations in the HCVcc system and the subgenomic replicon
assay (EC50-value ,30 mM). All DW 13 related analogues proved
toxic to the cells at ,10 mM (Figure S1).
Hemin Potentiates the Anti-HCV Activity of ART and
Derivatives
The malaria parasite is enriched in Hemin which results from
the digestion and degradation of haemoglobin. Hemin was
demonstrated to exert its anti-malarial activity, in part, by binding
to the ART molecule forming Hemin-ART adduct from which
radicals are released [28]. Hemin alone inhibits the replication of
the HCV infectious virus in a dose dependent manner as
measured by means of qRT-PCR (EC50 = 8.060.6 mM) and is
not toxic to Huh 7.5.1 at concentrations .50 mM. At 5 mM,
Hemin potentiates the antiviral activity of ART in the HCVcc
system by a factor 2-fold and in the replicon model by a factor 8.
The anti-HCV activity (in the subgenomic replicon system) of AJ-
002, but not of AJ-004, was potentiated 15-fold by Hemin
(Table 1). The combined treatment with Hemin was selective and
did not increase the toxicity profile at the concentrations tested.
Carbon-centered Radicals are not Crucial for the in vitro
Anti-HCV Activity for ART and Analogues in Cultures
Formation of carbon-centered radicals has been reported to be
critical for the in vitro anti-malarial activity of Artemisinin [29]. To
study whether these radicals are or are not required for the anti-
HCV activity of ART and its analogues, we combined a nitroxide
radical spin trap, 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO)
compound with either ART or TVN4 in the HCV replicon
system. TEMPO alone had no effect on the replication of HCV at
concentrations up to 200 mM. The combination of ART or TVN4
with TEMPO resulted only in a marginaly antagonistic effect
(Figure S2).
ART and its most Potent Analogues Partially Inhibit the
in vitro Replication of HCV by Induction of Reactive
Oxygen Species (ROS)
A possible mechanism by which ART and analogues may exert
their activity may be by the induction of reactive oxygen species
(ROS) [30]. If so, the addition of an anti-oxidant should reduce
their anti-HCV activity. We therefore combined in the HCV
subgenomic replicon (Huh 5-2) assay ART with L-N-acetylcyste-
ine (L-NAC); a compound that reduces reactive oxygen species
(ROS) formation. Whereas L-NAC alone has no effect on the
HCVcc replication at the concentration tested (HCV RNA
replication was 98%611 of UTC), the anti-HCV activity of
ART and its analogues (TVN4, AJ-001, AJ-002 and AJ-004) was
reduced by a factor 2 to 5 following the addition of L-NAC
(Table 1, Figure S3).
Discussion
Artemisinin (ART), a natural product isolated from the plant
Atremesia annua L, was originally discovered during the Vietnam
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War as a potent treatment for malaria [10]. Besides its anti-
malarial properties, ART also exerts in vitro anti-bacterial, anti-
inflammatory and anti-angiogenic activity [15,27,31]. ART also
inhibits the in vitro replication of the human cytomegalovirus
(HCMV) and the hepatitis B virus (HBV) [10,16,32] and its
derivative Artesunate inhibits the in vitro HIV replication [33]. We
demonstrated previously that ART inhibits the in vitro HCV
replicon replication [27]. Here, we report that ART inhibits also
the replication of infectious HCV JFH-1.
ART derivatives such as Artesunate, Artemether and Dihy-
droartemisinin [34–37], that are currently being used to treat
malarial infections, proved in our hands highly toxic in hepatoma
cell cultures (Huh 7.5.1) and were not considered for further study.
Interestingly, we were able to identify analogues that proved
markedly more potent as HCV inhibitors than the parent
compound.
In the subgenomic replicon system, the ART dimer (AJ-004)
was to be about ,3-fold more efficient in inhibiting the in vitro
HCV replicon replication as compared to the monomer AJ-001,
and was ,10-fold more potent than the monomer AJ-002 (benzyl
aldehyde derivative of ART). In cells infected with HCV JFH-1,
the ART monomers were roughly equipotent to the dimer. This
may suggest that the antiviral activity in the HCVcc-infected cells
may be determined by properties other than those related to the
endoperoxide bridge.
The malaria parasite has a high content of Hemin as a result of
the haemoglobin digestion and degradation. Thus, Hemin may
play a critical role in the anti-malarial activity of ART. It was
suggested that the iron centre of Hemin attacks the endoperoxide
bridge of the trioxane resulting in the cleavage of C3–C4 and the
release of radicals. Iron binds O1 (not O2) of ART to form an
iron-O-C bond (a Hemin-ART adduct) responsible for the
biological activity of the compound [38]. Surprisingly, Hemin
did not potentiate the anti-HCV activity of the most potent
derivative (AJ-004). In line with previous findings [39–41], we
showed that Hemin itself was able to inhibit the HCVcc
replication. It is thus possible that the role of iron in the anti-
HCV activity of ART and its derivatives may vary with the
chemical structure of the compound.
Figure 3. In vitro anti-HCV activity of Artemisinin and its selected analogues on the replication of infectious HCVcc as measured by
means of qRT-PCR (n=4). a) ART; b) TVN4; c) AJ-002 and d) AJ-004. Bars indicate the HCV RNA level as compared to control (%) and lines represent
the cell growth as compared to untreated controls (%).
doi:10.1371/journal.pone.0081783.g003
Table 1. Effect of ART and derivatives on Huh 5-2 HCV
replicon replication.
Compound
EC50
(mM)
CC50
(mM)
+Hemin
(5 mM) +L-NAC (5 mM)
ART 7567 .400 9.360.9 (8) .400 (25)
AJ-001 8.862.7 .133 4.662.8 (2) 2662 (23)
AJ-002 3068 .133 1.960.7 (15) 68622 (22)
AJ-004 3.262.4 .133 4.060.1 (0) 1764 (25)
TVN2 25613 3667 6.362 (+4) n.d
TVN4 36616 123614 1766 (+2) .100 (23)
TVN6 3.662.3 40620 n.d n.d
EC50: 50% effective concentration, CC50: 50% cytostatic concentration. Data
obtained from the measurement of the firefly luciferase activity, and are mean
values 6 SD for four independent experiments (expressed in mM).
Values between brackets indicate fold-change. At 5 mM, Hemin inhibits HCV
replicon replication by 30%.
doi:10.1371/journal.pone.0081783.t001
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Based on the observations made for the effect of the
combination of ART (as well as the analogue TVN4) with a
nitroxide radical spin trap (TEMPO) on anti-HCV activity, it is
unlikely that carbon centred radicals are as important for the anti-
HCV activity of ART as was suggested for the anti-malarial
activity of the compound.
The cleavage of the endoperoxide bridge within the ART
molecule results in the release of carbon radicals and reactive
oxygen species (ROS). The induction of ROS has been
demonstrated to regulate the replication of other viruses such as
HBV (negatively) [42] or HIV (positively) [43]. For HCV, it was
shown that peroxide treatment (which results in ROS induction),
at concentrations that were not toxic to the cells, resulted in the
disruption of active HCV replication complexes through reduction
of the amount of NS3 and NS5A in the replication complexes
[42]. The anti-HCV activity of ART induced by peroxides could
be negated by L-N-Acetylcysteine (L-NAC) [the molecule that
inhibits ROS generation]. Therefore, we studied the anti-HCV
activity of ART or analogues in combination with L-N-Acetyl-
cysteine (L-NAC). L-NAC reduced the anti-HCV activity of ART
and derivatives (2 to 5 fold) (Table 1).
In conclusion, we identified novel derivatives of ART that are
markedly more potent and selective in vitro HCV inhibitors than
the parent compound. It is suggested that at least part of the
antiviral activity is related to the induction of ROS. Carbon-
centred radicals are only marginally involved in the anti-HCV
activity of ART and derivatives thereof.
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